Journal article
A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma
Cancer, Vol.132(4), e70326
02/15/2026
DOI: 10.1002/cncr.70326
PMCID: PMC12912253
PMID: 41701511
Abstract
This phase 1b/2 study explored the safety and preliminary efficacy of the cabozantinib 40 mg daily and standard dose pembrolizumab combination therapy in frontline setting for patients with advanced or metastatic cutaneous melanoma. Toxicity was consistent with known safety profiles and efficacy data suggested an overall response rate of 45%, median progression‐free survival of 6.6 months, and median overall survival of 29.5 months.
Details
- Title: Subtitle
- A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma
- Creators
- Yousef Zakharia - University of IowaDonghyun Kim - Division of Hematology, Oncology, and Blood and Marrow Transplantation Department of Internal Medicine University of Iowa Health Care Iowa City Iowa USAMichele Freesmeier - University of IowaMelanie Frees - University of IowaSarah Mott - University of IowaVarun Monga - University of California, San FranciscoDouglas Laux - University of IowaAsad Javed - University of IowaJohn Rieth - University of IowaJohn Smestad - University of IowaMohammed Milhem - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.132(4), e70326
- DOI
- 10.1002/cncr.70326
- PMID
- 41701511
- PMCID
- PMC12912253
- NLM abbreviation
- Cancer
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Publisher
- WILEY
- Grant note
- Exelixis: IST 59
This study was funded by Exelixis, Inc. This study involves human participants and was approved by the University of Iowa institutional review board (approval number 201904712).
- Language
- English
- Date published
- 02/15/2026
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9985139313502771
Metrics
3 Record Views